Cencora’s Post

As we look ahead to 2025, healthcare is evolving towards a more patient-centric, efficient, and accessible future. As prescription drug costs rise, key industry shifts have presented valuable opportunities to explore reimbursement adjustments and enhance benefit management, ensuring better access to high-quality treatments. Learn more in AscellaHealth's latest article, How 2025 Will Transform Pharmacy Benefits for Payers, to discover how these shifts are primed to change the industry in the year ahead. Read more here: https://lnkd.in/eS-uVjGs #HealthcareTrends #Reimbursement #AscellaHealth #RareDisease #SpecialtyPharmacy #LifeSciences 

With prescription drug costs on the rise, AscellaHealth provides cost saving solutions to ensure patients are able to receive the quality of care they need. For more details on how AscellaHealth is navigating this industry shift, please refer to the article below. If interested, feel free to reach out 😃

Pharmacy Benefit Managers (PBMs) play a pivotal role in our healthcare system, acting as intermediaries between insurers, pharmacies, and manufacturers to manage prescription drug benefits. Their mission? To make medications more accessible and affordable for patients. With the complexity of drug pricing and reimbursement, PBMs have found themselves at the center of a heated debate. On one hand, they are seen as crucial players in negotiating discounts and rebates that can lower costs for insurers and consumers. On the other, questions arise about transparency, the impact on drug prices, and the overall effect on patient care. As we continue to navigate these challenges, it’s important to engage in open discussions about how PBMs can evolve to better serve all stakeholders. Collaboration, transparency, and patient-centric solutions must be at the forefront of this evolution. Together, we can work towards a healthcare system where every individual has access to the medications they need without the burden of excessive costs. 💡 How do you think PBMs can adapt to address the current challenges in healthcare? Share your thoughts! #Healthcare #PBM #PharmacyBenefitManagement #PatientCare #DrugPricing

For a nuanced and detailed look into potential PBM reform, we suggest reading this report. It reinforces the important work PBMs perform in negotiating drug costs for payers and patients, a role we understand firsthand as partners of several specialty PBMs. #Pharmacy #Healthtech #Healthcare https://lnkd.in/g5u5hGPg

U.S. pharmacy groups finally see results from their 15-year effort to raise awareness of the fact that the top three U.S. pharmacy benefits managers (who also own pharmacy chains, insurers and healthcare provider organizations) have deliberately inflated drug prices, limited patients’ access to medications and directly caused the closure of tens of thousands of community pharmacies. Says a Federal Trade Commission report: the PBMs “inflate prescription drug costs and interfere with patient care for their own financial benefit” and “have sought to use their position to artificially reduce reimbursement rates for competing pharmacies.” Read more here: https://lnkd.in/gyprmFtX

What does the future hold for Medicare? SVP Andrew Cournoyer delves into the critical impacts from the election—like a staggering 26% reduction in Prescription Drug Plan offerings – and how this may effect pharma leaders in Pharmalive. With potential payer consolidations and shrinking benefits on the horizon, the choices we make now could redefine health care for millions. #2024Election #MedicareFuture #HealthcarePolicy

𝗧𝗵𝗲 𝗙𝗧𝗖 𝗶𝘀𝘀𝘂𝗲𝗱 𝗮𝗻 𝗶𝗻𝘁𝗲𝗿𝗶𝗺 𝗿𝗲𝗽𝗼𝗿𝘁 𝘀𝗵𝗲𝗱𝗱𝗶𝗻𝗴 𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝘁𝗵𝗲 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗶𝗺𝗽𝗮𝗰𝘁 𝗼𝗳 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗿𝘀 (𝗣𝗕𝗠𝘀) 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗽𝘁𝗶𝗼𝗻 𝗱𝗿𝘂𝗴 𝗺𝗮𝗿𝗸𝗲𝘁. The largest PBMs manage nearly 95% of prescriptions, their vertical integration and market concentration have raised concerns about affordability and accessibility of medications. 𝙒𝙚𝙡𝙡 𝙩𝙝𝙖𝙣𝙠𝙨 𝙛𝙤𝙧 𝙘𝙖𝙩𝙘𝙝𝙞𝙣𝙜 𝙪𝙥! This report underscores how PBMs can influence drug availability and pricing, affecting patient care. It also highlights challenges faced by independent pharmacies due to unfair contractual terms. Transparency issues and compliance hurdles further underscore the need for continued scrutiny and regulatory action to ensure fair competition and affordable healthcare for all Americans. Learn more by reviewing the link in the comments. #Healthcare #PBMs #FTC #AffordableHealthcare #Prescriptions

Medical cost growth is estimated to reach its highest level in 13 years in 2025, according to a report by consultancy PwC. The increase is driven by "inflationary pressures, growing prescription drug spending — including on pricey weight loss medications — and rising utilization of behavioral healthcare, according to the report." More from HCdive: https://ow.ly/Uo2830sFke7 #healthcare #healthcarecosts #behavioralhealth #healthcaresystems

It's been three years since CMS required hospitals and payers to publish their commercial, Medicare Advantage, and Managed Medicaid negotiated rates. Today, biopharma manufacturers are tapping into this publicly available dataset to uncover competitive insights and shape strategies that drive Market Access, Pricing, and Reimbursement efforts. We will be talking more in-depth at the IntegriChain Access Insights Conference on Oct 14-16th and showing real data-driven examples and uses cases of how pharma manufacturers are leveraging transparency data to enable their commercial strategy and success. See you there. #pricetransparency #drugpricing #pharma

In just a few weeks, open enrollment begins for the more than 63 million people enrolled in Medicare programs in the U.S. During this time, many will evaluate and select a Part D plan that best meets their health needs. In a recent article for Pharmaceutical Commerce Magazine, PAN Foundation Chief Mission Officer Amy Niles, outlined the two important changes coming to Medicare Part D on January 1, 2025—the Medicare Part D cap and the Medicare Prescription Payment Plan. To learn more about these changes, read the full article here: https://ow.ly/i7Qe50SZJay